EGFR and non-small cell lung carcinoma: Afatinib was approved by the US Food and Drug Administration (FDA) in July 2013 for first-line treatment of patients with metastatic NSCLC whose tumors express EGFR mutations with exon 19 deletions or exon 21 (L858R; National Cancer Institute [NCI], 2013a).